Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT positive Imatinib prostate neuroendocrine neoplasm no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01799278 Phase II Alisertib A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer Completed USA 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Terminated ITA | GBR | FRA | ESP 1
NCT03582475 Phase I Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Completed USA 0
NCT03837353 Phase Ib/II DKN-01 DKN-01 + Docetaxel A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Terminated USA 0
NCT03910660 Phase Ib/II Pembrolizumab + Talabostat mesylate A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer Active, not recruiting USA | GBR 0
NCT04090775 Phase II Cyclophosphamide + Ipilimumab + Nivolumab A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma Completed USA 0
NCT04179864 Phase I Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ESP | BEL 0
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Recruiting USA 0
NCT04471727 Phase Ib/II Atezolizumab + HPN328 HPN328 Study in Patients With Advanced Cancers Associated With Expression of DLL3 Recruiting USA 0
NCT04702737 Phase I Tarlatamab A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer Active, not recruiting USA | NLD | GBR | FRA | ESP | BEL | AUT | AUS 1
NCT04709276 Phase II Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) Recruiting USA 0
NCT04926181 Phase II Apalutamide + Cetrelimab Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Active, not recruiting USA 0
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT05268666 Phase Ib/II JBI-802 A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05413421 Phase I ORIC-944 Study of ORIC-944 in Patients With Metastatic Prostate Cancer Recruiting USA 0
NCT05563558 Phase II Cabazitaxel + Carboplatin + Pembrolizumab Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (PEAPOD_FOS) Recruiting ESP 0
NCT05599984 Phase I ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors Recruiting USA | ESP | DEU | AUS 3
NCT05605522 Phase I 225Ac-FPI-2059 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours Recruiting USA | AUS 0
NCT05652686 Phase I PT217 A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study) Recruiting USA 0
NCT05691465 Phase II lutetium Lu 177 dotatate Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Recruiting USA 0
NCT05988918 Phase II CEP-11981 Multicenter Trial of ESK981 in Patients With Select Solid Tumors Recruiting USA 0
NCT06094842 Phase I L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Not yet recruiting USA 0
NCT06406465 Phase II Belinostat + Cisplatin + Etoposide A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Not yet recruiting USA 0